U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
TC Biopharm Announces Appointment of New Board Members
EDINBURGH, Scotland, Feb. 22, 2022 -- (Healthcare Sales & Marketing Network) -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allo... Biopharmaceuticals, Oncology, Personnel TC Biopharm, T cell therapy, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2022 Category: Pharmaceuticals Source Type: news
What Are Some Mast Cell Disorders?
Discussion
Mast cells (MCs) were first discovered by Paul Ehrlich in 1878. Previously in 1869, Nettleship and Tay described a toddler with chronic urticaria and a brown skin lesion which is believed to be the first reported case of mastocytosis. Urticaria pigmentosa was a term first used by Sangster in 1878, and in 1936 the term mastocytosis was used.
“Mast cells first evolved 500 million years ago in Ascidians (sea squirts), providing host innate immunity against bacteria and parasites….MCs gained additional functions regulating inflammation, wound healing, coagulation, adaptive immunity and acute allergic res...
Source: PediatricEducation.org - February 21, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
In study led by UCLA professor, woman with HIV is in remission
UCLA researchers speaking at the Conference on Retroviruses and Opportunistic Infections have presented the first case of a U.S. woman living with HIV-1 that is in remission.The woman, who was diagnosed with acute HIV in 2013 and acute myeloid leukemia in 2017, received umbilical cord blood cells as a treatment for her cancer. The leukemia has been in remission for four-and-a-half years, and there has been no rebound of HIV in the 14 months since antiretroviral therapy ended.The woman was part of a multicenter study that was funded by the National Institutes of Health and led by Dr. Yvonne Bryson, chief of pediatric i...
Source: UCLA Newsroom: Health Sciences - February 17, 2022 Category: Universities & Medical Training Source Type: news
Blast Counts Not Enough to Distinguish MDS From AML, Experts Say Blast Counts Not Enough to Distinguish MDS From AML, Experts Say
Oncologists argue that in differentiating myelodysplastic syndrome from acute myeloid leukemia, more than just bone marrow blast cutoff should be considered.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Polygenic Score Helps Guide Choice of Chemo for Pediatric AML
TUESDAY, Feb. 1, 2022 -- A polygenic score derived from pharmacogenomic evaluation of cytarabine (ara-C) pathway can help personalize treatment for pediatric patients with acute myeloid leukemia (AML), according to a study published online Jan. 18... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2022 Category: Pharmaceuticals Source Type: news
Surrogate Endpoints Acceptable in AML Trials, Says FDA Surrogate Endpoints Acceptable in AML Trials, Says FDA
In the case of drugs used for newly diagnosed acute myeloid leukemia (AML), surrogate endpoints have been validated, says the US Food and Drug Administration.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Long-Term Outcomes Described for Survivors of Childhood ALL
TURSDAY, Jan. 20, 2022 -- In an article published online Dec. 29 in Cancers, long-term adverse and positive outcomes are described for survivors of childhood acute lymphoblastic leukemia (ALL).
Charlotte Sleurs, Ph.D., from the University Hospital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 20, 2022 Category: Pharmaceuticals Source Type: news
Survival Increase Seen for Adults With Relapsed Ph+ ALL
TUESDAY, Jan. 18, 2022 -- Real-world data show steady improvement in overall survival (OS) for patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who experienced relapse after allogeneic hematopoietic cell transplantation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2022 Category: Pharmaceuticals Source Type: news
Survival Increase Seen for Adults With Relapsed Philadelphia-positive ALL
TUESDAY, Jan. 18, 2022 -- Real-world data show steady improvement in overall survival (OS) for patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who experienced relapse after allogeneic hematopoietic cell transplantation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2022 Category: Pharmaceuticals Source Type: news
Improved Survival in ALL Patients Who Relapse After Transplant Improved Survival in ALL Patients Who Relapse After Transplant
Survival has steadily improved over the past 20 years for adult patients with Ph+ acute lymphoblastic leukemia (ALL) who relapse after a transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Novel Agents for Adult ALL: Is it Curtains for Chemo? Novel Agents for Adult ALL: Is it Curtains for Chemo?
Tyrosine kinase inhibitors and novel agents like bi-specific T-cell engager and antibody drug conjugates have diminished the need for chemotherapy in adults with acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS
New findings provide preliminary evidence to use aggressive supportive treatment of COVID-19 in patients with acute leukemias and myelodysplastic syndromes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Myeloid Patients Respond Robustly to Moderna COVID Vaccine Myeloid Patients Respond Robustly to Moderna COVID Vaccine
Robust responses to COVID vaccination were seen in patients with acute myeloid leukemia and myelodysplastic syndrome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
